Advisory Board Includes Leading Experts In Membrane Proteins, Mass Spectrometry, Molecular Endocrinology
SAN DIEGO, August 12, 2002 HK Pharmaceuticals™, Inc. today announced members of its Scientific Advisory Board, which include Dr. Ira Goldfine, President of the Western Chapter of the American Diabetes Association; Prof. Franz Hillenkamp, co-inventor of MALDI mass spectrometry;
Dr. Joseph Loo, Director of UCLA Mass Spectrometry and Proteomics Technology Center; Dr. John Walker, 1997 Nobel Laureate in Chemistry; and Dr. Hubert Kster, HK Pharmaceuticals CEO and inventor of the Companys chemistry-based protein target discovery approach.
We have assembled a carefully selected team of the worlds leading scientists in each of their scientific disciplines. The board now represents the foremost expertise in the areas most critical to HK Pharmaceuticals approach: capture and analysis of membrane proteins, highly specific identification and characterization of proteins by mass spectrometry, and selection of appropriate disease models for the development of new compound leads.
The caliber of the board further represents the significance and uniqueness of HK Pharmaceuticals proprietary approach in identifying new, more highly characterized protein targets for drug development, said Dr. Köster, HK Pharmaceuticals Founder and CEO.
About the Scientific Advisory Board Members:
Ira Goldfine, M.D.
President of the Western Chapter of the American Diabetes Association
Dr. Ira Goldfine joins HK Pharmaceuticals scientific advisory board as a leading expert in molecular endocrinology, diabetes, biochemistry, cell biology and molecular biology. He is currently President of the Western Chapter of the American Diabetes Association; Professor of Medicine and Physiology, University of California, San Francisco; and Director of Mt.
Zion Diabetes and Endocrine Research, University of California, San Francisco. His many scientific accomplishments include identifying the cholecystokinin receptor; cloning of the insulin receptor; determining the role of the insulin receptor in breast cancer biology; and identifying PC-1 as a potential cause of type 2 diabetes mellitus.
Prof. Franz Hillenkamp, Ph.D.
Director Emeritus of the Institute of Medical Physics and Biophysics Universität Münster, Germany
Dr. Franz Hillenkamp is a renowned expert in mass spectrometry and became a scientific advisor to the Company in January 2002, shortly after its inception. Prof. Hillenkamp is most notably recognized as the co-inventor of Matrix Assisted Laser Desorption Ionization (MALDI) mass spectrometry (MS).
The invention of MALDI MS brought about an evolution in the speed, sensitivity and simplicity of biomolecule analysis and is an important component of HK Pharmaceuticals approach for protein target identification. Prof. Hillenkamp is Director Emeritus of the Institute of Medical Physics and Biophysics Universität Münster, Germany and Visiting Professor at the Harvard Medical School in Boston. Prior to this, Dr. Hillenkamp was Professor of Biophysics and Medical Faculty at J.W. Goethe Universität in Frankfurt, Germany.
Joseph Loo, Ph.D.
Professor of Biological Chemistry and Biochemistry, University of California Los Angeles, and
Director of UCLA Mass Spectrometry and Proteomics Technology Center
Dr. Loo joins HK Pharmaceuticals scientific advisory board as an expert on the uses of mass spectrometry in biomedical research and has performed pioneering work in industry and academic settings on its use for the characterization of proteins, post-translational modifications, and non-covalent biomolecule interactions.
Dr. Loo was previously Group Leader of the Biological Mass Spectrometry and co-leader of the Proteomics division at Parke-Davis Pharmaceuticals, now Pfizer.
Sir John Walker, D. Phil.
Director of The Medical Research Council’s Dunn Human Nutrition Unit
1997 Nobel Laureate in Chemistry
Dr. John Walker joins HK Pharmaceuticals scientific advisory board as one of the world’s leading experts on membrane proteins. Dr. Walker has received many national and international awards for his innovations in chemistry-based approaches to study proteins, most notably the Nobel Prize in 1997 for elucidation of the enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP).
He is currently Director of The Medical Research Council’s Dunn Human Nutrition Unit in Cambridge, U.K. He is also a Fellow of The Royal Society and a Foreign Member of The Netherlands Academy of Arts and Sciences.
Hubert Köster, Ph.D.
Founder and CEO, HK Pharmaceuticals
Dr. Hubert Köster is a renowned biochemist and a pioneer in the areas of genetic engineering, chemical synthesis of DNA and DNA analysis, with further scientific expertise in protein design, molecular biology and mass spectrometry. Dr. Köster’s seminal patent covering automated oligonucleotide synthesis has enabled the amplification and synthesis of DNA, a critical step in genetics research.
HK Pharmaceuticals is the fourth company that he has founded since 1981. The others are Sequenom, Inc. MilliGen/Biosearch (the biotech division of Millipore) and Biosyntech GmbH. In 1978, he was appointed tenured professor of organic chemistry and biochemistry at Hamburg University.